Wednesday, September 30, 2026
Approved
approved Note: Approved 2026-09-30 as CAMZYOS (SUPPL NDA214998). Auto-resolved from data/drugs.json by scripts/pdufa/resolve-outcomes.cjs on 2026-10-06; 0d from the PDUFA date.
Drug Information
- Drug Name
- Camzyos (mavacamten) (CT.gov)
- Application Type
- sNDA
- FDA Designations
- Priority Review
- Indication
- Symptomatic obstructive hypertrophic cardiomyopathy (oHCM) in adolescents (12 to <18 years)
- Approved As
- Camzyos (mavacamten)
Filing Details
- Company
- Bristol Myers Squibb →
- Stock Ticker
- BMY
- Source
- company press release →
What is a PDUFA Date?
A PDUFA (Prescription Drug User Fee Act) date is the FDA's target deadline to complete review of a drug application. The FDA aims to make an approval decision by this date.
- Standard Review: 10 months from filing acceptance
- Priority Review: 6 months from filing acceptance
- Possible Outcomes: Approval, Complete Response Letter (CRL), or extension
Explore Bristol Myers Squibb
View Bristol Myers Squibb's full pipeline, approved drugs, and clinical trials.
Data sourced from SEC EDGAR filings. Last updated: 2026-06-30. Report an issue